000046561 000__ 01035cam\a22003735i\4500
000046561 001__ 46561
000046561 003__ SzGeWIPO
000046561 005__ 20230509113020.0
000046561 006__ m\\\\eo\\d\\\\\\\\
000046561 007__ cr bn |||m|||a
000046561 008__ 221017s2021\\\\nyu\\\\\o\\\\\000\0\eng\d
000046561 035__ $$a(OCoLC)1348116844
000046561 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046561 041__ $$aeng
000046561 24500 $$aItaly: Aspen.
000046561 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2021
000046561 300__ $$a1 online resource
000046561 336__ $$atext$$2rdacontent
000046561 337__ $$acomputer$$2rdamedia
000046561 338__ $$aonline resource$$bcr$$2rdacarrier
000046561 4901_ $$aInternational Review of Intellectual Property Law & Competition Law,$$x0018-9855 ;$$vVolume 52, Issue 3
000046561 542__ $$fhttps://1.next.westlaw.com/Copyright
000046561 588__ $$aCrossref
000046561 590__ $$aPublished online: 2021
000046561 650_0 $$aIntellectual property.
000046561 650_4 $$aCompetition law$$zEurope
000046561 650_4 $$aPharmaceuticals
000046561 7731_ $$tInternational Review of Intellectual Property Law & Competition Law
000046561 7731_ $$wIIC
000046561 830_0 $$aInternational Review of Intellectual Property Law & Competition Law ;$$vIIC 2021, 52(3), 363-369
000046561 85641 $$uhttps://www.westlaw.com/Document/I03192BE09E4711EB80EEB106AF76DF66/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046561 904__ $$aArticle
000046561 980__ $$aIIC